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Cervical squamous cell carcinoma
Prognosis
Objective. Atypical chemokine receptors (ACRs), including CCX-CKR, DARC, and D6, have been reported to
be involved in cancer invasion and metastasis. The objective of this study was to investigate the prognostic
importance of ACRs in patients with cervical squamous cell carcinoma (CSCC).
Methods. The expression of three ACRs was investigated by immunohistochemical (IHC) examination in a
total of 317 cervical specimens including 40 normal cervical tissues, 50 cases of carcinoma in situ of cervix
(CIS), and 227 cases of CSCC by immunohistochemistry.
Results. The expression rate of DARC and CCX-CKR in CSCC, CIS, and normal cervix increased gradually
(p b 0.01). D6 expression is decreased in CSCC compared to either in CIS or in normal cervix (p b 0.05). In
addition, the expression of CCL2 and CCL19 was inversely associated with ACR expression (p b 0.05), while
that of LCA was positively correlated with ACR expression (p b 0.05). Moreover, DARC expression,
CCX-CKR expression, and ACR coexpression were negatively correlated with lymph node metastasis
(P b 0.01). D6 expression and ACR coexpression were negatively related to tumor size (p = 0.018) and re-
currence (p = 0.028). In multivariate Cox regression analysis, CCX-CKR expression was a positive indicator
for overall survival (p = 0.008), and D6 expression was an independent predictor of both overall and
recurrence-free survival (p = 0.041) in CSCC.
Conclusions. Our results suggest that the loss of ACRs may play important roles in the tumorigenesis and
migration of cervical cancer. ACR expression may be considered as prognostic markers in patients with CSCC.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Cervical cancer is the second most common malignancy of female
reproductive system [1]. One of the most important prognostic pa-
rameter in patients with cervical cancer is regional lymph node me-
tastasis [2]. About one-half of the cervical cancer patients with
pelvic lymph node metastasis will have recurrence of disease, with
most of them dying of uncontrolled disease [3]. The reported 5-yearg).
this work.
Inc. Open access under CC BY-NC-ND licensesurvival rate for patients who undergo relapse ranges from 3 to 13%
[4,5], while there is the lack of predictive markers for lymph nodeme-
tastasis in patients with cervical cancer.
Chemokines and their receptors, such as CXCL12/CXCR4, CCL19
(CCL21)/CCR7, and CXCL13/CXCR5, have been implicated mostly in
cell migration [6]. Recently, increasing attention has been drawn to
atypical chemokine receptors (ACRs), which comprise a group of 7
transmembrane domain proteins structurally similar to G protein-
coupled receptors [7]. However, atypical chemokine receptors do not
induce classical signaling via the typical G protein-mediated pathways
[8]. This may be due to the lack of canonical DRYLAIV motif within the
second intracellular loop, which normally enables G protein coupling
and induces the G protein-mediated signaling [9]. The ACR family, in-
cluding Duffy antigen receptor for chemokines (DARC), D6, and
Chemocentryx chemokine receptor (CCX-CKR), has the potential to.
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covered as the Duffy red blood group antigen, and it mediates the inter-
nalization of inﬂammatory chemokines of the CC (cysteines next to
each other) and CXC (cysteines separated by a single amino acid)
groups [11]. D6 binds multiple inﬂammatory CC chemokines, while it
does not recognize homeostatic CC chemokines [12]. CCX-CKR was
recently discovered and was found to localize predominantly in the
epithelial cells of heart and lung [13]. Previous studies have shown
that ACRs are involved in the process of tumor progression and metas-
tasis [14,15]. As chemokines contribute to immune suppression, tumor
inﬁltration, angiogenesis, and migration [16], ACRs inhibit tumor
progression by competitively binding to chemokines and in turn de-
creasing their bioactivities [17]. However, there is no published report
of whether the expression of ACRs correlates with progression or clini-
cal outcomes of cervical cancer.
In this study, we report for the ﬁrst time the characterization of
DARC, D6, and CCX-CKR expression in human cervical squamous cell
cancer. We found that the expression of DARC and CCX-CKR was con-
versely correlated with lymph node status. Multivariate analysis sug-
gested that D6 and CCX-CKR expression were independent prognostic
markers for CSCC patients. Our results strongly suggest that ACRs
might play an anticancer role in cervical cancer development and
might be valuable prognostic andmetastatic markers for CSCC patients.
Material and methods
Patients and tissue specimens
A total of 317 parafﬁn-embedded samples were obtained from CSCC
patients, whounderwent radical hysterectomy at Sun Yat-SenUniversi-
ty Cancer Center between Jan 2001 and June 2006. The samples were
composed of 40 normal cervical tissues, 50 CIS, and 227 CSCC speci-
mens. For the use of these clinical materials for scientiﬁc purposes,
prior patient's consent and approval from the Institute Research Ethics
Committee were obtained. None of the patients had received chemo-
therapy or radiotherapy before surgery. After surgery, patients were
treatedwith adjuvant radiotherapy or concurrent chemoradiation ther-
apy, depending on the lymph node status, the stage of the disease, the
parametrial status, and tumor differentiation, according to the national
guidelines. Postoperative radiotherapy was given to 65 patients. Post-
operative chemotherapy was administered to 110 patients. Patients
with lymph node metastasis received both chemotherapy and radio-
therapy postoperatively. The clinical stage of the patients was classiﬁed
according to the International Federation of Gynecology and Obstetrics
criteria as follows: 130were allocated to stage IB1, 38 to stage IB2, 40 to
stage IIA1, 13 to stage IIA2, and 8 to stage IIB. The median age of the pa-
tients was 42.7 years (range 25–68 years).
Immunohistochemistry
IHC analysis was performed to examine protein expression of DARC,
D6, CCX-CKR, chemokine (C–C motif) ligand 2 (CCL2), chemokine (C–C
motif) ligand 19 (CCL19), and leukocyte common antigen (LCA). Brieﬂy,
freshly cut 4 μmsectionswere deparafﬁnized and rehydrated in declin-
ing grades of ethanol. Antigen retrieval was performed by submerging
the sections into a 10 μmol/L citrate buffer solution (pH 6.0) for
10 min in a microwave oven. The slides were then treated with 3% hy-
drogen peroxide inmethanol to quench the endogenous peroxidase ac-
tivity, followed by incubation with 1% ﬁsh skin gelatin to block the
nonspeciﬁc staining. Tissue sections were incubated overnight with an-
tibodies against DARC (Abcam, 1:250), D6 (Abcam, 1:250), CCX-CKR
(Abcam, 1:250), LCA (Abcam, 1:500), CCL2 (Abcam, 1:100), and
CCL19 (Abcam, 1:100). After washing, the sections were incubated
with prediluted secondary antibody (Abcam), followed by further incu-
bation with 3,3-diaminobenzidine tetrahydrochloride (DAB). Finally,the slides were counterstained with hematoxylin and mounted in an
aqueous mounting medium.
All stained slides were separately evaluated by two pathologists.
For DARC, D6, CCX-CKR, CCL2, and CCL19, the IHC score was deﬁned
by multiplying the percentage of cytoplasmic positive cells by the in-
tensity. The intensity of stained cells was graded semi-quantitatively
into four levels: 0 (no staining); 1 (weak staining = light yellow); 2
(moderate staining = yellow brown) and 3 (strong staining =
brown); and the percentage was scored as: 0, negative; 1, 10% or
less; 2, 11% to 50%; 3, 51% to 80%; or 4, 80% or more positive cells.
The scoring system for DARC, D6, and CCX-CKR was deﬁned as nega-
tive for score 0 and as positive for scores of 1–12, whereas that for
CCL2 and CCL19 was deﬁned as negative for scores of 0–3, and as pos-
itive for scores of 4–12. Two or three coexpression of ACRs was
regarded as the coexpression of ACRs. For LCA, scoring was undertak-
en using a Chalkley point array [18]. In brief, three hot spots with the
highest density of positive cells were selected per tumor. A 25 cross
hair grid was used to score each hot spot at a magniﬁcation of
×200. Positive immune cells that touched or overlapped with tumor
epithelial compartments were counted as stained cells. A region was
considered positive if there were more than ﬁve stained cells per
unit area, and was considered negative if there were 0–5 stained
cells per unit area. The cutoff values were chosen on the basis of a
measure of heterogeneity with the log-rank test statistical analysis
with respect to overall survival and recurrence-free survival.
Follow-up and statistical analysis
All statistical analyses were carried out using SPSS (version 16.0,
Chicago, USA) statistical software. Follow-up was available for all pa-
tients with a median time of 60.4 months (range 0.5–131.6 months).
The overall survival and recurrence-free survival were calculated as
the time from the date of the primary surgery to the date of death
or ﬁrst recurrence. Survival of patients was estimated by Kaplan–
Meier analysis and the differences were compared by the log rank
test. Cox proportional hazards multivariate regression model was
used to select independently signiﬁcant prognostic factors for CSCC.
The correlation between ACR expression and clinicopathologic fea-
tures was assessed using the χ2 test or Fisher's exact test, while the
correlation between ACRs with CCL2, CCL19, and LCA staining was
evaluated using the Spearman's rank. P b 0.05 in all cases was consid-
ered statistically signiﬁcant.
Results
Expression of ACRs in CSCC, CIS, and normal cervical tissues
To investigate the potential roles of ACRs in the development and
progression of cervical cancer, we determined the expression of DARC,
D6, and CCX-CKR in 227 CSCC, 50 CIS, and 40 normal cervical tissues.
The three ACR proteins were mainly located in the cytoplasm of
tumor cells, but rarely in the nucleus. The representative immunostain-
ing of DARC, D6, and CCX-CKR in normal cervical tissues (Fig. 1, A–C),
CIS (Fig. 1, D–F), and CSCC (Fig. 1, G–L) was shown in Figure 1. Normal
cervical tissue showed positive DARC in 39 (97.5%), D6 in 32 (80.0%),
and CCX-CKR in 40 (100%) cases, CIS presents 42 (84.0%), 44 (88.0%),
and 43 (86.0%), and CSCC positively stained 168 (74.0%), 162 (71.4%),
and 179 (78.9%), respectively (Table 1).
Correlation of ACR expression with CCL2, CCL19, and LCA
Since chemokines play a crucial role inmodulating immune response,
we assessed the correlation of ACR expression with the expression of
their chemokine ligands (CCL2 for DARC and D6, CCL19 for CCX-CKR).
We also analyzed the correlation of ACR expression with lymphocyte in-
ﬁltration by evaluating the expression of LCA, amarker of leukocytes. The
Fig. 1. Representative immunostaining of DARC, D6, and CCX-CKR in normal cervical tissues (A–C), carcinoma in situ of cervix (D–F), and cervical squamous cell cancer (G–I,
positive; J–L, negative). Scale bar, 100 μm.
183T. Hou et al. / Gynecologic Oncology 130 (2013) 181–187representative IHC data was shown in Figure S1. The expression of CCL2
was inversely associated with DARC (Spearman's rho (ρ) = −0.146,
p = 0.028) expression, D6 (ρ = −0.159, p = 0.017) expression, and
ACR coexpression (ρ = −0.216, p = 0.001). The expression of CCL19
was inversely associated with CCX-CKR (ρ = −0.167, p = 0.012)
expression andACR coexpression (ρ = −0.141, p = 0.033). The expres-
sion of LCA was positively correlated with DARC expression (ρ = 0.203,
p = 0.002), D6 expression (ρ = 0.146, p = 0.028), and ACR co-
expression (ρ = 0.136, p = 0.040) (Table S1).Table 1
Distribution of DARC, D6, and CCXCKR in CSCC, carcinoma in situ of cervix, and normal cer
Characteristic DARC D6
+ n(%) − n(%) P + n(%) − n(%)
Invasive cancer 168(74.0) 59(26.0) 0.002 162(71.4) 57(28.6)
Carcinoma in situ 42(84.0) 8(16.0) 44(88.0) 6(12.0)
Normal cervix 39(97.5) 1(2.5) 32(80.0) 8(20.0)Expression of ACRs is associated with CSCC clinical features
To further investigate the roles ACRs in the tumorigenesis and de-
velopment of CSCC, we examined the correlation between ACRs and
the clinical characteristics in 227 CSCC cases. Our data showed that
DARC expression was signiﬁcantly correlated with lymph node in-
volvement (P b 0.001), that D6 expression was strongly correlated
with tumor size (p = 0.018) and tumor recurrence (p = 0.028),
and that CCX-CKR expression was associated with tumor stagevix.
CCX-CKR Coexpression
P + n(%) − n(%) P + n(%) − n(%) P
0.033 179(78.9) 48(21.1) 0.005 97(49.5) 99(50.5) 0.601
43(86.0) 7(14.0) 27(54.0) 23(46.0)
40(100) 0(0) 23(57.5) 17(42.5)
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0.003) (Table 2). In addition, the coexpression of the three ACRs
was signiﬁcantly correlated with tumor stage (p = 0.032), tumor
size (p = 0.003), tumor recurrence (p b 0.001), and lymph node sta-
tus (p = 0.006) (Table 2). There was no signiﬁcant relationship be-
tween ACR expression and patient age or tumor differentiation.
Patient survival analysis indicated that the D6 and CCX-CKR expres-
sion in CSCC signiﬁcantly linked to patients' survival time, signifying
that D6 positive expression was correlated with favorable overall sur-
vival and recurrence-free survival (Fig. 2, A–B), and that CCX-CKR pos-
itive expressionwas correlated with longer overall survival time (Fig. 2,
C–D). However, there was no signiﬁcant difference between DARC pos-
itive and negative groupswith respect to clinical survival time (Fig. 2, E–
F). Moreover, patients with tumors exhibiting the coexpression of ACRs
had signiﬁcantly longer overall and recurrence-free survival compared
with tumors without ACR coexpression (Fig. 2, G–H). These results sug-
gest that ACRs may be associated with disease development in CSCC.
Univariate and multivariate Cox regression analysis for prognosis of
patients with CSCC
In the univariate Cox proportional hazard regression model analysis
shown in Table 3, tumor size (p = 0.043 and p = 0.045, respectively),
lymph node metastasis (p = 0.033 and p = 0.037, respectively), LCA
expression (p = 0.023 and p = 0.046, respectively), D6 expression
(p = 0.003 and p = 0.028, respectively), and ACR coexpression
(p = 0.003 and p b 0.001, respectively) were signiﬁcantly correlated
with both overall and recurrence-free survival. The CCX-CKR expression
(p b 0.001) and FIGO stage (p = 0.024) were signiﬁcantly associated
with overall survival. In a multivariate Cox regression analysis shown
in Table 4, CCX-CKR expression showed signiﬁcant association with
overall survival (p = 0.004). D6 expression was an independent pre-
dictor of both overall and recurrence-free survival (p = 0.027 and
p = 0.028, respectively).
Discussion
In the current study, we observed that the expression rate of DARC
and CCX-CKR decreases as CSCC progresses to more advanced stages.
We also found that the CCL2 expression was inversely associated with
DARC expression, D6 expression, and ACR coexpression, that the
CCL19 expression was inversely correlated with CCX-CKR expression
and ACR coexpression, and that the LCA was positively correlated
with DARC expression, D6 expression, and ACR coexpression. More-
over, we demonstrated that D6 expression and ACR coexpressionTable 2
Distribution of ACR expression in CSCC patients according to clinicopathologic characteristi
Characteristic No. DARC (+) N (%) P D6 (+) N (%) P
Age (y) 0.762 0.6
≤40 105 79 (75.2) 73 (69.5)
>40 122 89 (73.0) 89 (73.0)
FIGO stage 0.246 0.1
IB1 130 100 (76.9) 98 (75.4)
>IB1 97 68 (70.1) 64 (66.0)
Differentiation 0.566 0.0
Grade 1/2 84 64 (76.2) 66 (78.6)
Grade 3 143 104 (72.7) 96 (67.1)
Timor size 0.131 0.0
≤4 cm 174 133 (76.4) 131 (73.6)
>4 cm 53 35 (66.0) 31 (64.2)
LN metastasis b0.001 0.2
− 194 154 (79.4) 141 (72.7)
+ 33 14 (41.2) 21 (63.6)
Recurrence 0.392 0.0
− 196 147 (75.0) 145 (74.0)
+ 31 21 (67.7) 17 (54.8)
Note: ACRs including DARC, D6, and CCX-CKR.could predict favorable overall and recurrence-free survival, while
CCX-CKR expression was positively associated with overall survival,
but not with recurrence-free survival in CSCC patients. Furthermore,
we proposed that DARC and CCX-CKR expression were negatively
correlated with lymph node metastasis in patients with CSCC. Our
study suggests that ACRs not only represent valuable biomarkers for
the prediction of CSCC prognosis, but also play crucial roles in cervical
cancer progression.
It is becoming clear that ACRs might act as decoy receptors to de-
plete extracellular chemokines, and hence inhibit angiogenesis in the
primary tumor and reduce metastasis [19,20]. DARC is a transcytosis
receptor that binds with ELR + (glutamine–leucine–arginine motif
in N-terminus) CXC and some CC chemokines and causes ligand inter-
nalization without lysosomal degradation [21]. Accumulating evi-
dence suggests that the enhanced expression of DARC attenuates
cancer growth and metastasis [22], while the lack of DARC expression
might lead to enhanced tumor growth [23]. D6 acts as a scavenger for
inﬂammatory CC chemokines. It binds and clears the chemokines
CCL2 and CCL5, which are important components of cancer-related
inﬂammation [21]. Similarly to D6, CCX-CKR binds with high afﬁnity
to chemokines CCL19, CCL21, CCL25, and CXCL13. These chemokines
participate in CCR7/CCL19 (CCL21), CCR9/CCL25, and CXCR5/CXCL13
axes which are involved in cancer cell migration [24]. All these stud-
ies have indicated that ACRs may contribute to the initiation and pro-
gression of cancer.
To investigate whether ACRs are correlated to the progression of
CSCC, we characterize the expression of DARC, D6, and CCX-CKR in
normal cervical tissues, CIS, and CSCC specimens. Our ﬁndings
showed that the expression rate of ACRs in CSCC, CIS, and normal cer-
vix increased in gradual ascending order. An exception to this is the
ﬁnding of expression peak of D6 in CIS. This ﬁnding may be related
to the function of inﬂammatory molecules such as TGF-β, which has
been reported to be increased in CIN [25], and which could upregulate
the expression level of D6 [26]. Statistical analysis revealed that DARC
expression signiﬁcantly correlates with lymph node status, that D6
expression correlates with tumor size and recurrence, and that
CCX-CKR expression correlates with FIGO stage, tumor size, and
lymph node status. Our observations are in agreement with previous
studies demonstrating that the expression of ACRs was associated
with tumor stage [27]. The correlations of ACR expression with
lower tumor stage suggested that ACRs may play an anticancer role
in the tumorigenesis and development of CSCC.
Considering the roles of chemokines in driving lymphocyte inﬁl-
tration, we examined the correlation of ACR expression with the ex-
pression of their chemokine ligands and LCA. We found that thecs.
CCX-CKR (+) N (%) P Coexpression (+) N (%) P
59 0.255 0.112
79 (75.2) 48 (45.7)
100 (82.0) 69 (56.5)
21 0.033 0.032
109 (83.8) 75 (57.6)
70 (72.1) 42 (43.3)
66 0.936 0.693
66 (78.6) 45 (53.6)
113 (79.0) 72 (50.3)
18 0.026 0.003
143 (82.2) 100 (56.9)
36 (67.9) 17 (34.0)
88 0.003 0.006
159 (82.0) 108 (55.6)
20 (60.6) 9 (27.3)
28 0.103 b0.001
158 (80.6) 111 (56.6)
21 (67.7) 6 (19.4)
Fig. 2. Kaplan–Meier analysis of overall survival and recurrence-free survival in relation to D6 (A–B), CCX-CKR (C–D), and DARC (E–F) expression, and ACR coexpression (G–H) in
227 cervical squamous cell cancer (CSCC) patients.
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pression, which agrees with previous studies that DARC and D6medi-
ate effective scavenging of CCL19, and that CCX-CKR scavenges CCL2
[19,24,28]. Interestingly, the expression of LCA was positively corre-
lated with DARC expression, D6 expression, and ACR coexpression,
which does not go along with their described anti-chemotaxisproperty. It is possible that ACR expression may represent a mecha-
nism to activate immune response. This hypothesis is supported by
McKimmie and colleagues [26], who proposed that D6 may be criti-
cally involved in the initiation of immune responses. It is also possible
that, beyond their roles in scavenging chemokines, ACRs may activate
intracellular signaling pathways involved in lymphocyte chemotaxis.
Table 3
Univariate Cox regression analysis of overall survival (OS) and recurrence-free survival









Age (>40 vs ≤40) 2.415 (0.906–6.438) 0.078 1.989 (0.965–4.099) 0.062
FIGO stage
(>IB1 vs IB1)
3.280 (1.169–9205) 0.024 2.054 (0.997–4.234) 0.050
Differentiation
(Grade 3 vs 1/2)
1.590 (0.631–4.007) 0.325 1.148 (0.550–2.396) 0.714
Timor size (>4 cm
vs ≤4 cm)
2.618 (1.033–6.639) 0.043 2.099 (1.018–4.327) 0.045
LN metastasis
(+ vs −)
2.910 (1.091–7.761) 0.033 2.280 (1.049–4.957) 0.037
DARC expression
(+ vs −)
0.490 (0.190–1.266) 0.141 0.682 (0.321–1.449) 0.320
D6 expression
(+ vs −)




0.189 (0.074–0.479) b0.001 0.512 (0.241–1.088) 0.082
ACR coexpression
(+ vs −)
0.110 (0.025–0.477) 0.003 0.205 (0.084–0.500) b0.001
CCL2 expression
(+ vs −)
1.782 (0.707–4.490) 0.220 1.109 (0.538–2.285) 0.779
CCL19 expression
(+ vs −)
1.276 (0.455–3.580) 0.643 1.387 (0.639–3.014) 0.408
LCA expression
(+ vs −)
0.182 (0.042–0.793) 0.023 0.424 (0.182–0.984) 0.046
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putative signaling scaffold β-arrestin in response to chemokines [29].
We further investigate the relationship betweenACRexpression and
prognosis in CSCC patients. We found that patients without D6 expres-
sion had shorter overall and recurrence-free survival time. In addition,
we observed that CCX-CKR expression is positively correlated with
overall survival in CSCC. When analyzing the prognostic value of
DARC expression in CSCC patients, the ﬁnding is no longer signiﬁcant.
This result might be due to different efﬁciency of the three ACRs in che-
mokine internalization and subsequent lysosomal degradation. An as-
sociation between ACR expression and clinical outcome has been
reported in several studies. Feng et al. demonstrated that lack or lowTable 4
Multivariate Cox regression analysis of overall survival (OS) and recurrence-free
survival (RFS) in patients with CSCC.






Age (>40 vs ≤40) 2.564 (0.922–7.129) 0.071 2.276 (1.075–4.821) 0.055
FIGO Stage
(>IB1 vs IB1)
2.811 (0.929–8.501) 0.067 2.047 (0.955–4.383) 0.065
Differentiation
(Grade 3 vs 1/2)
1.482 (0.512–4.292) 0.468 1250 (0.562–2.780) 0.584
Timor Size (>4 cm vs
≤4 cm)
1.213 (0.431–3.410) 0.714 1.027 (0.48–2.354) 0.950
LN Metastasis
(+ vs −)
1.238 (0.379–4.051) 0.724 1.055 (0.398–2.794) 0.914
DARC expression
(+ vs −)
0.703 (0.217–2.280) 0.557 0.977 (0.406–2.354) 0.959
D6 expression
(+ vs −)
0.333 (0.125–0.885) 0.027 0.451 (0.222–0.916) 0.028
CCX-CKR expression
(+ vs −)
0.247 (0.094–0.647) 0.004 0.750 (0.330–1.709) 0.494
CCL2 expression
(+ vs −)
1.073 (0.374–3.082) 0.895 1.081 (0.495–2.363) 0.844
CCL19 expression
(+ vs −)
1.346 (0.442–4.095) 0.601 1.248 (0.547–2.845) 0.599
LCA expression
(+ vs −)
0.366 (0.096–1.393) 0.140 0.490 (0.209–1.147) 0.100CCX-CKR expression indicated a poor survival rate in breast cancer pa-
tients [30]. Sun et al. reported that high DARC expression correlated
with a higher survival rate in laryngeal squamous cell carcinoma [31].
Wu et al. discovered that D6 expression was positively correlated to
disease-free survival in breast cancer [18], which is consistent to our ob-
servation. Furthermore, we found that coexpression of the three ACRs is
inversely associated with overall and recurrence-free survival. In accor-
dance with our ﬁnding, Zeng et al. suggested that the coexpression of
ACRs was associated with better overall survival and recurrence-free
survival in breast cancer [27]. These results imply a combined role of
these decoy receptors. The combined ACR expression could enhance
the prognostic value of single ACR alone in patients with CSCC. A possi-
ble criticism of our ﬁndings could be that the FIGO stage is a prognostic
factor of overall but not of recurrence-free survival. The ﬁnding is prob-
ably due to variation and small sample size. Moreover, the administra-
tion of postoperative adjuvant therapy may also affect patients'
recurrence.
It is noteworthy that DARC and CCX-CKR have been found, in our
study, to be inversely correlatedwith lymph node status, which concurs
with previous studies in that ACR expressionwas associatedwith tumor
progression and metastasis. Similarly to our study, Bandyopadhyay et
al. demonstrated that interaction between DARC and Kangai 1 (KAI1)
signiﬁcantly suppressed tumor cell proliferation and metastasis by
modulating the expression of senescence controlling genes, T-box tran-
scription factor 2 (TBX2) and cyclin-dependent kinase inhibitor 1 (p21)
[32]. Addison et al. described that tumors derived from DARC-
expressing cells had signiﬁcantly decreased tumor associated vascula-
ture and metastatic potential as compared to tumors derived from
DARC-negative cells [33]. Cheng et al. suggested that CCX-CKR could in-
hibit the growth and metastasis of breast cancer by attracting and se-
questrating chemokines [34]. Zeng et al. reported that the expression
of the ACRs was inversely associated with lymph node metastasis
[27]. Taken together, these observations suggest that DARC and
CCX-CKR may serve as a potentially metastatic indicator and an impor-
tant growth regulator for CSCC.
To our knowledge, the present study is the ﬁrst to analyze the prog-
nostic values of ACRs in CSCC. In conclusion, we have found that the
three ACRs could be used as prognostic markers in CSCC patients.
More importantly, we have found that CSCC patients without DARC or
CCX-CKR expression are more prone to have lymph node metastasis,
and that without D6 expression are more likely to have recurrent dis-
ease. Further studies are needed to elucidate the roles of ACRs during
the development of CSCC, and it may lead to new therapeutic target
for cervical cancer.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygyno.2013.04.015.
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